Affimed Touts Encouraging Patient Responses For Its NK Cell Therapy In Lymphoma Settings
Affimed N.V. (NASDAQ: AFMD)
Affimed Presents Findings From The Dose-Escalation Phase Of The First-In-Human Study Of AFM24 In Patients With EGFR-Positive Solid Tumors At AACR Annual Meeting
Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced data
Earnings Scheduled For March 31, 2022
Companies Reporting Before The Bell
• Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.
Piper Sandler Initiates Coverage On Affimed with Overweight Rating, Announces Price Target of $7
Piper Sandler analyst Do Kim initiates coverage on Affimed (NASDAQ:AFMD) with a Overweight rating and announces Price Target of $7.
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
20 Stocks Moving in Thursday’s Pre-Market Session
Gainers
Mercurity Fintech Holding Inc. (NYSE: MFH) rose 91% to $4.03 in pre-market trading.
Mid-Afternoon Market Update: Dow Falls 200 Points; Rockwell Medical Shares Spike Higher
Toward the end of trading Wednesday, the Dow traded down 0.58% to 35,930.89 while the NASDAQ fell 0.27% to 15,930.79. The S&P also fell, dropping 0.23% to 4,690.24.
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours.
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.